<DOC>
	<DOCNO>NCT01320592</DOCNO>
	<brief_summary>This study phase I , single arm , open-label trial PD0332991 combination Paclitaxel patient Rb-expressing metastatic breast cancer . Up 20 patient anticipate enrolled reach MTD PD0332991 combination Paclitaxel . Once MTD establish , additional expand cohort 10 patient enrol dose establish RP2D , obtain additional safety data perform exploratory biomarker study .</brief_summary>
	<brief_title>PD0332991/Paclitaxel Advanced Breast Cancer</brief_title>
	<detailed_description>This study phase I , single arm , open-label trial PD0332991 combination paclitaxel patient Rb-expressing metastatic breast cancer . Patients treat show schema . Up 20 patient anticipate enrolled reach MTD PD0332991 combination Paclitaxel . Once MTD establish , additional expand cohort 10 patient enrol dose estalish RP2D , obtain additional safety data perform exploratory biomarker study . The primary endpoint assess one cycle therapy . Patients remain study dose limit toxicity , disease progression physician/patient discretion . Safety assessment continue durationof patient participation .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patient must histologically cytologicallyconfirmed metastatic breast cancer . Any ER , PR Her2 status allow . Tumor must express Retinoblastoma ( Rb ) protein , define measureable stain immunohistochemistry Male female &gt; 18 year age day sign informed consent . Patient must receive &lt; prior cytotoxic regimen metastatic breast cancer . This include cytoxic regimen use adjuvant setting . Performance status 01 ECOG Performance Scale life expectancy &gt; 3 month . patient doseescalation portion trial must evaluable disease , define either measurable ( RECIST ) nonmeasurable disease ( e.g . bone mets , pleural effusion lymphangitic spread ) . Measurable disease require patient expand RP2D cohort . The subject must adequate organ function , define follow : Bilirubin &lt; 1.5 x UNL calculate creatinine clearance &gt; 60 mL/min , subject without liver metastasis : alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5 x ULN For subject without extensive bone metastasis : alkaline phosphatase level &lt; 2.5 x ULN . For subject extensive bone metastasis : alkaline phosphatase level &lt; 5 x ULN . The subject must adequate marrow function , define follow Absolute neutrophil count ( ANC ) &gt; 1500/mm Platelets &gt; 100,000/mm Hemoglobin &gt; 9 g/dL Female patient childbearing potential must negative serum urine pregnancy test within 72 hour prior receive first dose study medication agree use effective method contraception study . Patient must capable , must voluntarily agree participate give write informed consent . Patient must able swallow capsule surgical anatomical condition preclude patient swallow absorb oral medicatios ongoing basis . Prior taxane therapy adjuvant metastatic setting allow . Concomitant use biophosphonates allow . Patients stable , treated CNS disease eligible . Patient chemotherapy , radiotherapy hormonal therapy within 3 week ( 6 week nitrosoureas , mitomycin C bevacizumab ) , recover adverse event due previous agent administer 4 week prior Study Day 1 . If patient residual toxicity prior treatment , toxicity must &lt; Grade 1. patient less 4 week post major surgical procedure ( surgical wound must fully heal ) . For purpose criterion , major surgical procedure define one require administration general anesthesia . Patient know active CNS metastasis and/or carcinomatous meningitis . However , patient CNS metastasis ( include brain metastasis ) complete course radiotherapy eligible study provide clinically stable . Oral corticosteroid control CNS symptom allow . Patient known hypersensitivity component study drug analog . The subject uncontrolled intercurrent illness include , limited Ongoing active infection Diabetes mellitus Hypertension Symptomatic congestive heart failure , unstable angina pectoris , stroke myocardial infarction within 3 month . Patient baseline neuropathy &gt; grade 2 Patients know allergic reaction Paclitaxel IV Contrast Dye despite standard prophylaxis . The subject pregnant breastfeed The subject know positive human immunodeficiency virus ( HIV ) . Note : baseline HIV screening require . The subject unable eor unwilling abide study protocol cooperate fully investigator designee .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Patient must histologically cytologically-confirmed metastatic</keyword>
	<keyword>breast cancer</keyword>
	<keyword>Any ER , PR Her2 status allow .</keyword>
	<keyword>Tumor must express Retinoblastoma ( Rb ) protein , define</keyword>
	<keyword>measurable stain immunohistochemistry invasive tumor component</keyword>
	<keyword>&lt; 3 prior cyttoxic chemotherapy regimens metastatic disease .</keyword>
	<keyword>Performance status 0-1 ECOG Performance Scale life expectancy &gt; 3 month .</keyword>
	<keyword>Patient must evaluable disease . Measureable disease require .</keyword>
	<keyword>The subject adequate organ function</keyword>
</DOC>